Christoph Welsch

Summary

Publications

  1. doi request reprint Clinical relevance of HCV antiviral drug resistance
    C Welsch
    J W Goethe University Hospital, Department of Internal Medicine I, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Curr Opin Virol 2:651-5. 2012
  2. pmc Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease
    Christoph Welsch
    Division of Infectious Diseases, Department of Medicine, Inflammatory Diseases Institute, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7292, USA
    Gastroenterology 142:654-63. 2012
  3. doi request reprint New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
    Christoph Welsch
    Department of Internal Medicine I, J W Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Gut 61:i36-46. 2012
  4. pmc Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease
    Christoph Welsch
    Division of Infectious Diseases, Department of Medicine and the Lineberger Comprehensive Cancer Center, Chapel Hill, University of North Carolina at Chapel Hill, North Carolina, USA
    Antimicrob Agents Chemother 56:1907-15. 2012
  5. pmc Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
    Christoph Welsch
    Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbrucken, Germany
    Genome Biol 9:R16. 2008
  6. doi request reprint Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir
    Wolf Peter Hofmann
    Department of Internal Medicine I, Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 16:695-704. 2011
  7. doi request reprint Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C
    Ulrike Mihm
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    J Hepatol 50:49-58. 2009
  8. pmc Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus
    Tetsuro Shimakami
    Division of Infectious Diseases, Department of Medicine, Inflammatory Diseases Institute, and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Gastroenterology 140:667-75. 2011
  9. pmc Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III
    Seungtaek Kim
    Inflammatory Diseases Institute, 8 034 Burnett Womack CB 7292, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7292, USA
    J Virol 85:6645-56. 2011
  10. pmc Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells
    Hiromichi Dansako
    Division of Infectious Diseases, Department of Medicine, and the Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS Pathog 9:e1003345. 2013

Collaborators

Detail Information

Publications14

  1. doi request reprint Clinical relevance of HCV antiviral drug resistance
    C Welsch
    J W Goethe University Hospital, Department of Internal Medicine I, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Curr Opin Virol 2:651-5. 2012
    ..Knowledge on molecular escape mechanisms of resistant variants, their time to wild-type reversal and potential persistence is of upmost importance to design treatment strategies for patients with previous DAA-treatment failure...
  2. pmc Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease
    Christoph Welsch
    Division of Infectious Diseases, Department of Medicine, Inflammatory Diseases Institute, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7292, USA
    Gastroenterology 142:654-63. 2012
    ..However, clinical trials have revealed rapid selection of resistant mutants, most of which are considered to be pre-existing variants...
  3. doi request reprint New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
    Christoph Welsch
    Department of Internal Medicine I, J W Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Gut 61:i36-46. 2012
    ..The novel agents in clinical development are paving the way for future interferon-sparing regimens...
  4. pmc Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease
    Christoph Welsch
    Division of Infectious Diseases, Department of Medicine and the Lineberger Comprehensive Cancer Center, Chapel Hill, University of North Carolina at Chapel Hill, North Carolina, USA
    Antimicrob Agents Chemother 56:1907-15. 2012
    ..Reduced structural flexibility could impact the Val55 variant's ability to adapt for NS3 domain-domain interaction and might explain the virus yield drop observed in variant strains...
  5. pmc Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus
    Christoph Welsch
    Department of Computational Biology and Applied Algorithmics, Max Planck Institute for Informatics, 66123 Saarbrucken, Germany
    Genome Biol 9:R16. 2008
    ..These mutations are located in the protein interior and far away from the ligand binding pocket...
  6. doi request reprint Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir
    Wolf Peter Hofmann
    Department of Internal Medicine I, Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 16:695-704. 2011
    ..Ribavirin increases early and sustained virological response rates in patients chronically infected with HCV who receive pegylated interferon-α and novel HCV protease inhibitors...
  7. doi request reprint Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C
    Ulrike Mihm
    Medizinische Klinik I, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    J Hepatol 50:49-58. 2009
    ..Viral RNA is cleaved by RNase L at UU/UA dinucleotides. The clinical relevance of RNase L cleavage for response to an interferon-alpha-based therapy in chronic hepatitis C is unknown...
  8. pmc Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus
    Tetsuro Shimakami
    Division of Infectious Diseases, Department of Medicine, Inflammatory Diseases Institute, and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Gastroenterology 140:667-75. 2011
    ..Many of these significantly impair the replication fitness of HCV RNA replicons. However, it is not known whether these mutations also adversely affect infectious virus assembly and release, processes in which NS3 also participates...
  9. pmc Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III
    Seungtaek Kim
    Inflammatory Diseases Institute, 8 034 Burnett Womack CB 7292, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7292, USA
    J Virol 85:6645-56. 2011
    ..Thus, despite low overall sequence homology, the production of infectious virus is regulated similarly in JFH-1 and H77S viruses by a conserved function associated with a C-terminal Ser/Thr cluster in domain III of NS5A...
  10. pmc Class A scavenger receptor 1 (MSR1) restricts hepatitis C virus replication by mediating toll-like receptor 3 recognition of viral RNAs produced in neighboring cells
    Hiromichi Dansako
    Division of Infectious Diseases, Department of Medicine, and the Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America
    PLoS Pathog 9:e1003345. 2013
    ....
  11. doi request reprint Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS
    Harald Farnik
    Pharmazentrum frankfurt ZAFES, Institut fur Klinische Pharmakologie, Klinikum der Johann Wolfgang Goethe Universitat Frankfurt, Theodor Stern Kai 7, Haus 74, 60590 Frankfurt am Main, Germany
    J Chromatogr B Analyt Technol Biomed Life Sci 877:4001-6. 2009
    ..It is suitable to quantify the concentrations of the hepatitis C virus protease inhibitors boceprevir and telaprevir in human plasma...
  12. pmc Dimerization of the hepatitis C virus nonstructural protein 4B depends on the integrity of an aminoterminal basic leucine zipper
    Martin Walter Welker
    Klinikum der Johann Wolfgang Goethe Universitat, Medizinische Klinik 1, Theodor Stern Kai 7, Frankfurt am Main 60590, Germany
    Protein Sci 19:1327-36. 2010
    ..In conclusion, our data indicate NS4B-homodimerization and that this interaction is facilitated by the aminoterminal part containing a bZIP motif...
  13. pmc Base pairing between hepatitis C virus RNA and microRNA 122 3' of its seed sequence is essential for genome stabilization and production of infectious virus
    Tetsuro Shimakami
    Division of Infectious Diseases, Department of Medicine, Inflammatory Diseases Institute and Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    J Virol 86:7372-83. 2012
    ..These data add to the current understanding of miR-122 interactions with HCV RNA but indicate that base pairing between miR-122 and the 5' 43 nt of the HCV genome is more complex than suggested by existing models...
  14. ncbi request reprint Pharmacokinetics of peginterferons
    Stefan Zeuzem
    Department of Medicine, Division of Gastroenterology, Hepatology, and Endocrinology, Saarland University Hospital, Homburg Saar, Germany
    Semin Liver Dis 23:23-8. 2003
    ..However, it remains unknown whether these differences in the initial viral decline predict differences in the primary clinical endpoint, sustained virological response...